Co-Authors
This is a "connection" page, showing publications co-authored by KIM-ANH DO and ANIRBAN MAITRA.
Connection Strength
0.469
-
Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv. 2024 Mar 15; 10(11):eadd9342.
Score: 0.059
-
Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Clin Chem. 2024 01 04; 70(1):102-115.
Score: 0.058
-
A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer. J Cancer Immunol (Wilmington). 2024; 6(4):148-153.
Score: 0.058
-
A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep Med. 2023 09 19; 4(9):101194.
Score: 0.057
-
CES2 sustains HNF4a expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Mol Metab. 2022 02; 56:101426.
Score: 0.051
-
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun. 2021 07 30; 12(1):4626.
Score: 0.049
-
Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2021 03; 160(4):1373-1383.e6.
Score: 0.047
-
CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol. 2020 Nov; 4:426-436.
Score: 0.047
-
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
Score: 0.043